Medical
-
According to VentiRx Pharmaceuticals, a Phase I clinical trial of its VTX-1463 nasal spray for the treatment of allergic rhinitis demonstrated that once-weekly administration of the drug produced a significantly greater reduction in total nasal… Read more . . .
-
GlaxoSmithKline has announced that the Relovair fluticasone furoate/vilanterol trifenatate DPI it is developing with Theravance showed good results in a Phase II study involving 60 COPD patients. Studies of the component drugs for asthma also… Read more . . .
-
A study by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) shows that a combination of tiotropium bromide with a low dose of inhaled corticosteroid (ICS) provides better… Read more . . .
-
Novartis has announced that its Phase III INSIST study shows that its once-daily Onbrez Breezhaler indacaterol DPI produces better bronchodilation in COPD patients than does twice-daily salmeterol. Onbrez also reduced the need for rescue medication,… Read more . . .
-
Boston Scientific has acquired Asthmatx, the developer of a bronchial thermoplasty procedure marketed as an alternative to inhaled medications for the treatment of severe asthma for an upfront payment of $193.5 million and future payments… Read more . . .
-
A PD study has shown no statistically significant difference in pulmonary artery pressure effects of Levadex inhaled dihydroergotamine (DHE) compared to placebo, according to MAP Pharmaceutical. The inhaled formulation had a smaller effect on pulmonary… Read more . . .
-
A study published in the American Journal of Respiratory and Critical Care Medicine found that teenagers who used acetaminophen at least once a month have a 250% higher risk of developing asthma than do non-users and… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden